
|Articles|March 1, 2004
CMS expands coverage for OPT with verteporfin
Washington, DC-The Centers for Medicare and Medicaid Services (CMS) once again plans to expand its coverage for ocular photodynamic therapy (OPT) with verteporfin (Visudyne, Novartis Ophthalmics).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
2
Metformin use associated with reduced incidence of intermediate AMD
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5




























